Anderson Monique L, Peterson Eric D, Peng S Andrew, Wang Tracy Y, Ohman E Magnus, Bhatt Deepak L, Saucedo Jorge F, Roe Matthew T
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):708-15. doi: 10.1161/CIRCOUTCOMES.113.000262. Epub 2013 Nov 12.
Cardiogenic shock is a deadly complication of an acute myocardial infarction (MI). We sought to characterize differences in patient features, treatments, and outcomes of cardiogenic shock by MI classification: ST-segment-elevation MI (STEMI) versus non-ST-segment elevation MI (NSTEMI).
We compared differences in care by the shock status of 235 541 patients with STEMI and NSTEMI treated at 392 US hospitals from 2007 to 2011. Cardiogenic shock occurred in 12.2% of patients with STEMI versus 4.3% of patients with NSTEMI. Compared with STEMI shock, NSTEMI shock was more likely in patients who were older and predominantly women; had diabetes mellitus, hypertension, previous heart failure, MI, or peripheral arterial disease; and who received coronary artery bypass grafting (11.6% versus 21.2%; P<0.0001) but less likely to have received percutaneous coronary intervention (84.2% versus 35.3%; P<0.0001). Compared with patients with STEMI presenting with shock at admission, patients with NSTEMI presenting with shock had longer delays to percutaneous coronary intervention (1.2 versus 3.2 hours) and coronary artery bypass grafting (7.9 versus 55.9 hours). Cardiogenic shock in patients with STEMI was associated with a lower mortality risk (33.1% shock versus 2.0% no shock; adjusted odds ratio, 14.1; 95% confidence interval, 13.0-15.4; interaction P value <0.0001) compared with patients with NSTEMI (40.8% shock versus 2.3% no shock, odds ratio, 19.0; 95% confidence interval, 17.1-21.2).
Cardiogenic shock is associated with high mortality in patients with STEMI and NSTEMI. However, urgent revascularization is more commonly pursued in patients with STEMI presenting with shock than in patients with NSTEMI. More research is needed to improve the outcomes for patients with MI presenting with shock, particularly those presenting with NSTEMI.
心源性休克是急性心肌梗死(MI)的一种致命并发症。我们试图通过MI分类(ST段抬高型MI [STEMI]与非ST段抬高型MI [NSTEMI])来描述心源性休克患者特征、治疗方法及预后的差异。
我们比较了2007年至2011年在美国392家医院接受治疗的235541例STEMI和NSTEMI患者因休克状态而导致的治疗差异。STEMI患者中心源性休克的发生率为12.2%,而NSTEMI患者中为4.3%。与STEMI休克相比,NSTEMI休克在年龄较大且以女性为主的患者中更常见;这些患者患有糖尿病、高血压、既往心力衰竭、MI或外周动脉疾病;并且接受冠状动脉旁路移植术的比例更高(11.6%对21.2%;P<0.0001),但接受经皮冠状动脉介入治疗的可能性较小(84.2%对35.3%;P<0.0001)。与入院时出现休克的STEMI患者相比,出现休克的NSTEMI患者接受经皮冠状动脉介入治疗的延迟时间更长(1.2小时对3.2小时),接受冠状动脉旁路移植术的延迟时间也更长(7.9小时对55.9小时)。与NSTEMI患者(休克患者为40.8%,无休克患者为2.3%,比值比为19.0;95%置信区间为17.1 - 21.2)相比,STEMI患者的心源性休克与较低的死亡风险相关(休克患者为33.1%,无休克患者为2.0%;调整后的比值比为14.1;95%置信区间为13.0 - 15.4;交互作用P值<0.0001)。
心源性休克与STEMI和NSTEMI患者的高死亡率相关。然而,与出现休克的NSTEMI患者相比,出现休克的STEMI患者更常进行紧急血运重建。需要更多研究来改善出现休克的MI患者的预后,尤其是那些出现NSTEMI的患者。